Keefe Bruyette says The Bancorp’s (TBBK) sale of the Aubrey building falling through is “concerning and raises questions” about the collateral value of the property. The buyer is walking away from $3M of earnest money and has up to $2.4M of sunk costs from required rehabilitation investments, the analyst tells investors in a research note. Keefe’s investigation indicates that the ultimate purchaser was a revenue-less biotech company that possibly couldn’t obtain reasonable financing terms. It has an Outperform rating on The Bancorp with a $70 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBBK:
- The Bancorp says apartment complex sale to terminate without buyer cure
- Bancorp Announces Key Approvals at Annual Meeting
- The Bancorp price target lowered to $57 from $67 at Raymond James
- The Bancorp price target lowered to $70 from $72 at Keefe Bruyette
- The Bancorp, Inc. Reports Strong Q1 2025 Earnings